Loading...
OTCM
FRTX
Market cap5mUSD
Feb 28, Last price  
0.94USD
Name

Fresh Tracks Therapeutics Inc

Chart & Performance

D1W1MN
P/E
P/S
0.70
EPS
Div Yield, %
Shrs. gr., 5y
143.31%
Rev. gr., 5y
37.62%
Revenues
8m
+15.31%
14,545,00012,003,00014,740,0005,512,0007,956,00012,686,0008,711,00030,018,00017,519,0007,718,00015,217,00020,950,00014,531,00013,819,0001,622,0007,917,0001,822,000404,0006,943,0008,006,000
Net income
-6m
L-72.44%
-23,733,000-24,357,000-23,148,000-35,894,000-36,896,000-28,558,000-30,385,000-7,283,000-22,899,000-31,238,000-16,492,000-9,238,000-8,973,000-12,960,000-16,254,000-25,945,000-20,903,000-39,521,000-20,661,000-5,694,000
CFO
-4m
L-77.54%
-21,069,000-22,781,000-15,668,000-24,182,000-30,867,000-21,452,000-28,228,000-3,848,000-17,574,000-29,798,000-9,806,000-6,948,000-8,388,000-8,601,0003,967,000-35,981,000-20,034,000-36,148,000-19,335,000-4,343,000

Profile

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
IPO date
Mar 10, 1993
Employees
13
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8,006
15.31%
6,943
1,618.56%
Cost of revenue
14,366
42,520
Unusual Expense (Income)
NOPBT
(6,360)
(35,577)
NOPBT Margin
Operating Taxes
(441)
Tax Rate
NOPAT
(6,360)
(35,136)
Net income
(5,694)
-72.44%
(20,661)
-47.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,569
1,233
BB yield
-126.38%
-29.27%
Debt
Debt current
49
Long-term debt
49
Deferred revenue
Other long-term liabilities
620
Net debt
(10,868)
(8,582)
Cash flow
Cash from operating activities
(4,343)
(19,335)
CAPEX
(47)
Cash from investing activities
(47)
Cash from financing activities
6,531
1,178
FCF
(6,270)
(35,143)
Balance
Cash
10,868
8,680
Long term investments
Excess cash
10,468
8,333
Stockholders' equity
(172,103)
(166,439)
Invested Capital
182,033
173,682
ROIC
ROCE
EV
Common stock shares outstanding
5,913
2,808
Price
0.88
-41.39%
1.50
-85.44%
Market cap
5,198
23.40%
4,212
-77.09%
EV
(5,670)
(4,370)
EBITDA
(6,319)
(35,547)
EV/EBITDA
0.90
0.12
Interest
5
9
Interest/NOPBT